For instance, CRC cells with acquired resistance to cetuximab, an epidermal growth factor receptor (EGFR) inhibitor, overexpressed SphK1, and its inhibition re-established sensitivity to the drug. This evidence concerns the gene SPHK1 and colorectal carcinoma.